Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
Trans-vaccenic acid (TVA), a long-chain fatty acid found in meat and dairy products from grazing animals such as cows and sheep, improves the ability of CD8+ T cells to infiltrate tumors and kill cancer cells, according to a new study by researchers from the University of Chicago.
UCLA researchers have developed a new treatment method using a tiny nanocapsule to help boost the immune response, making it easier for the immune system to fight and kill solid tumors.
At the UCLA Jonsson Comprehensive Cancer Center, scientists have uncovered a novel function for a protein known as extracellular signal-regulated kinase (ERK) within a pathway activated by interferon-gamma, capable of inducing cellular self-destruction.
A new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The University of Texas at Austin has found.
Researchers from University of British Columbia and Michigan State University have invented a system that can quickly and inexpensively detect airborne viruses using the same technology that enables high-speed trains.
A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?"
Novel blood testing technology being developed by researchers at the Johns Hopkins Kimmel Cancer Center that combines genome-wide sequencing of single molecules of DNA shed from tumors and machine learning may allow earlier detection of lung and other cancers.
Immune system T cells that should be able to kill cancer cells become dysfunctional or "exhausted" within hours of encountering a tumor, according to a study reported Aug. 3 in Nature Immunology.
Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells-;which play a key role in immune response-;that eradicated tumors and prevented their recurrence in mouse models of melanoma.
When does that seasonal tan turn into a melanoma risk? When might those extra pounds cause diabetes? Could severe head injuries cause Alzheimer’s to develop? In the grand scheme of things, genetics, lifestyle, and age are risk factors, with the solutions frequently appearing only after the unfortunate diagnoses.
Johns Hopkins Medicine scientists say they have developed a nanoparticle -; an extremely tiny biodegradable container -; that has the potential to improve the delivery of messenger ribonucleic acid (mRNA)-based vaccines for infectious diseases such as COVID-19, and vaccines for treating non-infectious diseases including cancer.
Acting as a team, twin stem cells activate the immune system to suppress tumor growth and prolong survival in representative preclinical models.
A potential immunotherapy method for treating metastatic melanoma is adoptive cell therapy (ACT). The method, which utilizes the use of immune cells extracted from the patient’s own tumors, could offer cancer patients new options for treatment by eschewing radiation therapies and harsh chemotherapy drugs.
According to a study conducted by UCLA, patients with advanced melanoma responded differently to PD-1 checkpoint blockade immunotherapy depending on a variety of variables, including whether or not they had previously received CTLA-4 blockade, another type of immunotherapy.
Even as pancreatic cancer treatments advance, only around 9% of patients live beyond five years. Scientists have failed to identify genetic distinctions that explain why some patients live for a long time and others do not, so they have moved their emphasis to the gut microbiome.
Cancer that has spread to areas like the lungs can apply the brakes to a natural pathway that should recruit killer T cells directly to where it has metastasized, scientists report.
In the future, vaccines may be delivered with a puff of air rather than a needle, according to the promising results of new research presented at a meeting of the American Chemistry Society this March.
Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies.
Most immunotherapies that aim to increase T cell activity are ineffective in treating estrogen receptor-positive (ER+) breast cancer. A new study of invasive ER+ breast cancers led by researchers at the University of Pittsburgh School of Medicine implies that targeting a different type of immune cell called macrophages may be a more effective approach.
Most immunotherapies, which aim to boost T cell activity, work poorly in treating estrogen receptor-positive (ER+) breast cancer.